[1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol,2018,3:383-403.
[2] Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet,2016,388:1081-1088.
[3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=04AFF9FB0F68EC73826EC45C613D1977?sequence=1.
[4] Cui F, Luo H, Wang F, et al. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine,2013,31:J36-42.
[5] World Health Organization. Tenofovir reduces mother-to-child transmission of hepatitis B: new study. http://www.who.int/hepatitis/news-events/hbvmtct tenofovir/en/.
[6] Hou J, Cui F, Ding Y, et al. Management Algorithm for Interrupting Mother to Child Transmission of Hepatitis B Virus. Clinical Gastroenterology and Hepatology,2018 (in press) .
[7] Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis,2016,16:1399-1408.
[8] Lazarus JV, Pericàs JM, Colombo M, et al. Viral hepatitis: "E" is for equitable elimination. J Hepatol,2018,69:762-764. |
